VBL Therapeutics (VBLT) Announces Topline Data from VB-111 Phase 2; OS Benefit Noted
Tweet Send to a Friend
VBL Therapeutics (Nasdaq: VBLT), announced top-line results from its exploratory Phase 2 study of VB-111 (ofranergene obadenovec) in patients with ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
